yahoo_financeOriginal article
LLY's Olumiant Gets FDA Nod for Expanded Use in Pediatric Hair Loss
RegulatoryapprovedOlumiantPositive
AI Analysis
Summary
Eli Lilly's Olumiant (baricitinib) has received FDA approval for an expanded indication in pediatric hair loss. The approval represents a label expansion for the JAK inhibitor.
Outcome Details
FDA approval for expanded use in pediatric hair loss
Importance:7/10
Sentiment:
0.80
FDA approvallabel expansionpediatric indicationdermatology
Related Companies
Read the original article
Published by yahoo_finance on September 28, 2026 2:03 PM